• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿尔茨海默病患者接受白蛋白置换的血浆置换治疗后的神经心理学、神经精神和生活质量评估：来自随机 AMBAR 研究的结果。

Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.

机构信息

Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.

Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

出版信息

Alzheimers Dement. 2022 Jul;18(7):1314-1324. doi: 10.1002/alz.12477. Epub 2021 Nov 2.

DOI:10.1002/alz.12477
PMID:34726348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9540900/
Abstract

INTRODUCTION

We report the effects of plasma exchange (PE) with albumin replacement on neuropsychological, neuropsychiatric, and quality-of-life (QoL) outcomes in mild-to-moderate Alzheimer's disease (AD) patients in a phase 2b/3 trial (Alzheimer's Management by Albumin Replacement [AMBAR] study).

METHODS

Three hundred forty-seven patients were randomized into placebo (sham-PE) and three PE-treatment arms with low/high doses of albumin, with/without intravenous immunoglobulin (IVIG). Specific test measurements were performed at baseline; month 2 (weekly conventional PE); months 6, 9, and 12 (monthly low-volume PE [LVPE]); and month 14.

RESULTS

The PE-treated mild-AD cohort improved their language fluency and processing speed versus placebo at month 14 (effect sizes: >100%; P-values: .03 to .001). The moderate-AD cohort significantly improved short-term verbal memory (effect sizes: 94% to >100%; P-values: .02 to .003). The progression of the neuropsychiatric symptoms of PE-treated was similar to placebo. Mild-AD patients showed improved QoL (P-values: .04 to .008).

DISCUSSION

PE-treated AD patients showed improvement in memory, language abilities, processing speed, and QoL-AD. No worsening of their psychoaffective status was observed.

摘要

简介

我们报告了在轻度至中度阿尔茨海默病（AD）患者的 2b/3 期试验（白蛋白替代治疗阿尔茨海默病管理[AMBAR]研究）中，用白蛋白替代物进行血浆置换（PE）对神经心理学、神经精神和生活质量（QoL）结果的影响。

方法

347 名患者被随机分为安慰剂（假 PE）和 3 个 PE 治疗组，分别接受低/高剂量白蛋白、有/无静脉注射免疫球蛋白（IVIG）治疗。在基线时、第 2 个月（每周常规 PE）、第 6、9 和 12 个月（每月低容量 PE [LVPE]）以及第 14 个月进行特定的测试测量。

结果

与安慰剂相比，PE 治疗的轻度 AD 队列在第 14 个月时提高了语言流畅性和处理速度（效应大小：>100%；P 值：.03 至.001）。中度 AD 队列的短期语言记忆显著改善（效应大小：94%至>100%；P 值：.02 至.003）。PE 治疗的神经精神症状进展与安慰剂相似。轻度 AD 患者的 QoL 得到改善（P 值：.04 至.008）。

讨论

PE 治疗的 AD 患者在记忆、语言能力、处理速度和 QoL-AD 方面有改善。未观察到其心理情感状态恶化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/45d88223f585/ALZ-18-1314-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/dca3235f3d20/ALZ-18-1314-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/354f7f78a445/ALZ-18-1314-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/7d36bf6ea3e1/ALZ-18-1314-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/d5e35280510a/ALZ-18-1314-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/679fbacf8279/ALZ-18-1314-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/45d88223f585/ALZ-18-1314-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/dca3235f3d20/ALZ-18-1314-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/354f7f78a445/ALZ-18-1314-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/7d36bf6ea3e1/ALZ-18-1314-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/d5e35280510a/ALZ-18-1314-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/679fbacf8279/ALZ-18-1314-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a09/9540900/45d88223f585/ALZ-18-1314-g006.jpg

相似文献

1
Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.阿尔茨海默病患者接受白蛋白置换的血浆置换治疗后的神经心理学、神经精神和生活质量评估：来自随机 AMBAR 研究的结果。
Alzheimers Dement. 2022 Jul;18(7):1314-1324. doi: 10.1002/alz.12477. Epub 2021 Nov 2.
2
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.一项针对阿尔茨海默病患者采用血浆置换联合白蛋白替代治疗的随机、对照临床试验：AMBAR 研究的主要结果。
Alzheimers Dement. 2020 Oct;16(10):1412-1425. doi: 10.1002/alz.12137. Epub 2020 Jul 27.
3
Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study.一项评估在轻度至中度阿尔茨海默病中用白蛋白替代物进行血浆置换的随机对照研究的神经影像学分析：AMBAR 研究的附加结果。
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4589-4600. doi: 10.1007/s00259-022-05915-5. Epub 2022 Jul 22.
4
Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study.AMBAR 研究中两种含白蛋白置换的血浆置换方式治疗老年阿尔茨海默病患者的可行性、安全性和耐受性。
J Clin Apher. 2023 Feb;38(1):45-54. doi: 10.1002/jca.22026. Epub 2022 Oct 28.
5
Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study.治疗性和低容量血浆置换对 AMBAR 研究中阿尔茨海默病患者临床实验室参数的影响。
Ther Apher Dial. 2023 Oct;27(5):949-959. doi: 10.1111/1744-9987.14002. Epub 2023 May 21.
6
Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.5%白蛋白血浆置换对阿尔茨海默病患者脑脊液和血浆β淀粉样蛋白浓度及认知结果的疗效和安全性：一项多中心、随机、对照临床试验
J Alzheimers Dis. 2017;56(1):129-143. doi: 10.3233/JAD-160565.
7
Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.采用血浆置换、白蛋白血液滤过及静脉注射免疫球蛋白联合疗法治疗阿尔茨海默病：AMBAR（通过白蛋白替代管理阿尔茨海默病）研究的理论依据及治疗方法
Neurologia. 2016 Sep;31(7):473-81. doi: 10.1016/j.nrl.2014.02.003. Epub 2014 Jul 9.
8
Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin.血浆置换联合 5%人血白蛋白治疗轻中度阿尔茨海默病患者的纵向神经影像学分析。
J Alzheimers Dis. 2018;61(1):321-332. doi: 10.3233/JAD-170693.
9
Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress.阿尔茨海默病白蛋白置换治疗血浆置换（AMBAR）试验：研究设计与进展
Alzheimers Dement (N Y). 2019 Feb 26;5:61-69. doi: 10.1016/j.trci.2019.01.001. eCollection 2019.
10
Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease.用白蛋白进行治疗性血浆置换：治疗阿尔茨海默病的新方法。
Expert Rev Neurother. 2021 Aug;21(8):843-849. doi: 10.1080/14737175.2021.1960823. Epub 2021 Aug 4.

引用本文的文献

1
Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease.阿尔茨海默病中肌肉减少症的危险因素识别及预测列线图的构建
Alzheimers Dement. 2025 Feb;21(2):e14503. doi: 10.1002/alz.14503. Epub 2025 Jan 8.
2
Plasma exchange with albumin replacement for Alzheimer's disease treatment induced changes in serum and cerebrospinal fluid inflammatory mediator levels.用白蛋白替代进行血浆置换治疗阿尔茨海默病可引起血清和脑脊液炎症介质水平的变化。
Ann Clin Transl Neurol. 2024 Dec;11(12):3280-3291. doi: 10.1002/acn3.52235. Epub 2024 Oct 30.
3
The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review.

本文引用的文献

1
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.一项针对阿尔茨海默病患者采用血浆置换联合白蛋白替代治疗的随机、对照临床试验：AMBAR 研究的主要结果。
Alzheimers Dement. 2020 Oct;16(10):1412-1425. doi: 10.1002/alz.12137. Epub 2020 Jul 27.
2
A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms.一项关于AMPA调节剂S47445治疗轻至中度阿尔茨海默病伴抑郁症状患者疗效和安全性的24周双盲安慰剂对照研究。
Alzheimers Dement (N Y). 2019 Jun 24;5:231-240. doi: 10.1016/j.trci.2019.04.002. eCollection 2019.
3
在阿尔茨海默病管理中使用白蛋白置换的血浆置换：一项范围综述。
Front Neurol. 2024 Sep 30;15:1443132. doi: 10.3389/fneur.2024.1443132. eCollection 2024.
4
Intrathecal Immunoselective Nanopheresis for Alzheimer's Disease: What and How? Why and When?鞘内免疫选择性纳滤治疗阿尔茨海默病：是什么，如何进行？为什么，何时进行？
Int J Mol Sci. 2024 Oct 2;25(19):10632. doi: 10.3390/ijms251910632.
5
Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer's Disease.低密度脂蛋白受体相关蛋白1作为阿尔茨海默病的潜在治疗靶点
Pharmaceutics. 2024 Jul 17;16(7):948. doi: 10.3390/pharmaceutics16070948.
6
Downregulation of miR-181c-5p in Alzheimer's disease weakens the response of microglia to Aβ phagocytosis.阿尔茨海默病中 miR-181c-5p 的下调削弱了小胶质细胞对 Aβ 吞噬的反应。
Sci Rep. 2024 May 20;14(1):11487. doi: 10.1038/s41598-024-62347-x.
7
Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy.阿尔茨海默病：对病理学、分子机制及治疗的见解
Protein Cell. 2025 Feb 1;16(2):83-120. doi: 10.1093/procel/pwae026.
8
Understanding treatment goals and their application in clinical trial design for patients with Alzheimer disease and caregivers.了解阿尔茨海默病患者及其照料者的治疗目标及其在临床试验设计中的应用。
Drugs Context. 2024 Apr 29;13. doi: 10.7573/dic.2023-11-6. eCollection 2024.
9
Application of a Novel Endpoint Staging Framework: Proof of Concept in the AMBAR Study.新型终点分期框架的应用：AMBAR 研究中的概念验证。
J Alzheimers Dis. 2024;98(3):1079-1094. doi: 10.3233/JAD-231197.
10
A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease.阿尔茨海默病治疗的潜在分子药物靶点的全面综述。
Cent Nerv Syst Agents Med Chem. 2024;24(1):45-56. doi: 10.2174/0118715249263300231116062740.
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
随机试验：维鲁贝司他治疗前驱阿尔茨海默病。
N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.
4
Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress.阿尔茨海默病白蛋白置换治疗血浆置换（AMBAR）试验：研究设计与进展
Alzheimers Dement (N Y). 2019 Feb 26;5:61-69. doi: 10.1016/j.trci.2019.01.001. eCollection 2019.
5
Genetic data and cognitively defined late-onset Alzheimer's disease subgroups.遗传数据与认知定义的晚发性阿尔茨海默病亚组
Mol Psychiatry. 2020 Nov;25(11):2942-2951. doi: 10.1038/s41380-018-0298-8. Epub 2018 Dec 4.
6
One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study.上海轻度认知障碍队列研究的一年结果。
Curr Alzheimer Res. 2019;16(2):156-165. doi: 10.2174/1567205016666181128151144.
7
Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer's Disease Patients.阿尔茨海默病患者脑脊液和血浆中白蛋白氧化增加。
J Alzheimers Dis. 2018;63(4):1395-1404. doi: 10.3233/JAD-180243.
8
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.随机试验：维脑生素治疗轻中度阿尔茨海默病。
N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.
9
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.用于阿尔茨海默病所致轻度痴呆的 Solanezumab 试验。
N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971.
10
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.茚达品作为胆碱酯酶抑制剂辅助药物对阿尔茨海默病患者认知功能变化的影响：三项随机临床试验
JAMA. 2018 Jan 9;319(2):130-142. doi: 10.1001/jama.2017.20373.